Akebia Therapeutics, Inc. (AKBA) vs MacroGenics, Inc. (MGNX)
A side-by-side comparison of Akebia Therapeutics, Inc. and MacroGenics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 12:04 PM EDT
MGNX
MacroGenics, Inc.
$3.72HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — AKBA vs MGNX
growth of $100 · dividends reinvested · last 10yAKBA -89.8% (-20.4%/yr)MGNX -87.5% (-18.7%/yr)MGNX compounded faster over this window
AKBA MGNX
AKBA vs MGNX: by the numbers
- •AKBA is the larger company ($240M vs $236M market cap).
- •Both run net losses; MGNX's is the smaller (-8.70% vs -13.54% net margin).
- •MGNX grew revenue faster over the past five years (7.33% vs -0.26% CAGR).
Metrics side by side
Valuation
| Metric | AKBA | MGNX |
|---|---|---|
| P/S ratio | 1.10 | 1.41 |
| P/B ratio | 9.61 | 5.51 |
| FCF yield | 16.72% | N/A |
Profitability
| Metric | AKBA | MGNX |
|---|---|---|
| Gross margin | 79.48% | 71.12% |
| Operating margin | 9.95% | -48.72% |
| Net margin | -13.54% | -8.70% |
| ROE | -118.58% | -34.04% |
| ROIC | -7.08% | -16.87% |
Growth (annualized)
| Metric | AKBA | MGNX |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | 7.33% |
| Total return CAGR (5Y) | -20.07% | -28.42% |
Frequently asked
- Which has grown faster, AKBA or MGNX?
- Over the past five years, MGNX grew revenue faster — AKBA at a -0.26% CAGR versus MGNX at 7.33%.
- How have AKBA and MGNX total returns compared?
- Over the past 10 years, AKBA delivered -20.53% and MGNX delivered -18.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Akebia Therapeutics ROEMacroGenics ROEAkebia Therapeutics operating marginMacroGenics operating marginAkebia Therapeutics revenue growthMacroGenics revenue growthAkebia Therapeutics free cash flowMacroGenics free cash flow
Akebia Therapeutics & MacroGenics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.